Expression of HLA Class I and II on Peripheral Blood Lymphocytes in HBV Infection
Wang Chuan-xin,Wang Jin-feng,Liu Min,Zou Xiong,Yu Xiu-ping,Yang Xiao-jing,Zheng Gui-xi
DOI: https://doi.org/10.1097/00029330-200605010-00008
2006-01-01
Abstract:Persistent hepatitis B virus (HBV) infection is the most important reason for chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma.1 T lymphocytes, including CD4+ and CD8+ T cells, are major composition of host cellular immunity. Furthermore, CD8+ cells play a primary role in host immune reaction of anti-tumor and anti-infection. It has been confirmed that HBV infection leads to disorder of cellular immune function in patients, especially disorder in regulative function of T lymphocyte subgroups and cytokine.2 It has been paid more attention to the expression of HLA class I on hepatocytes infected by HBV and tumor cells, but less to the expression of HLA class I on peripheral blood lymphocytes in the past. In this study, we evaluated the expression of HLA class I and II on peripheral blood lymphocytes in patients with chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma and tried to provide new thought for the mechanism of disorder of celluar immunity. METHODS Subjects From November 2004 to August 2005, a total of 173 patients were selected from the Departments of Hepatopathy and Lemology at Qilu Hospital, Shandong University. There were 84 patients with chronic hepatitis B and 57 with hepatic cirrhosis, whose inclusion criteria was based on the Program of Prevention and Cure for Viral Hepatitis, 2000.3 There were 32 patients with hepatocellular carcinoma, whose inclusion criteria was based on the Criteria of the Clinical Diagnosis and Staging for Primary Liver Carcinoma, 2001.4 In the study, there were 51 normal control who were healthy volunteers with normal hepatic function, negtive serum HBV markers and had no severe patient history. All the subjects were drawn 2 ml of venous blood on an empty stomach at 7 − 8 am which was anticoagulated by EDTA-K2 to evaluate the expression of HLA class I and HLA class II on peripheral blood lymphocytes in patients with chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma. Cell line HepG2 cells were obtained from the Tumor Center of Qilu Hospital in Shandong University. These cells were routinely cultured in RPMI1640 medium (GIBCO, USA) containing 10% fetal bovine serum and penicinin-streptomycin, and were subcultured once every three days. Detection of HLA-I and HLA-II by FCM Labeled lymphocytes by antibody Four tubes marked as HLA-I-Ctr, HLA-II-Ctr, HLA-I, and HLA-II were prepared and 10 μl isotype control immunoglubin were taken into the tubes of HLA-I-Ctr and HLA-II-Ctr. Ten μl of anti-HLA-A, B, C-FITC and anti-HLA-II-DP, DQ, DR-FITC (BD, USA) were taken into the tubes of HLA-I and HLA-II respectively. One hundren μl of anticoagulated blood were added into all the above tubes, and reacted for 25 minutes from light. Then 2 ml of haemolysin (BD, USA) were added into all tubes, and reacted for 10 minutes, centrifuged for 5 minutes at 2000 r/min. Two ml of dilution were added into each tube, centrifuged for 5 minutes at 2000 r/min. The supernatant was discharged and sediment underlayer was mixed. Five hundred μl of dilution were added into each tube, and misced bene to float cells. Detected by flow cytometer Adjusting the instrument with Calibrite beads, control coefficient of variability less than 2% and consider the HLA-I-Ctr, HLA-II-Ctr as negative control. Circle the region of lymphocytes in the 2-Dimensional picture of forward scatter (FS) and side scatter (SS). Cells (104) were collected and evaluated their fluoresecence intensity of FITC which was magnified as logarithm. All the fluoresecence parameters were analyzed by Cell Quest Plot software. Killing activity of lymphokine activated killer cell Peripheral blood lymphocytes were sterilely prepared by Ficoll separating medium and diluted to 1 × 108/L with complete medium. Cells were incubated for 5 days in 5% CO2 incubator (Fisher Scientific, USA) at 37°C. Culture medium was added on the second day and the fourth day and the cells growth was observed under the inverted phase contrast microscope (Olympus Nikontex, Japan). The optimal choice 0.5 × 108/ml of target cells (HepG2 cells) were taken by CytoTox 96 non-radioactive cytotoxicity assay, which contains lysis solution, substrate mix, stop solution and so on. The concentration of effector cells (LAK cells, target cells) was adjusted to 20:1 with complete medium. Cells were divided into seven groups: ① effector cell spontaneous LDH release group, ② experimental group, ③ target cell spontaneous LDH release group, ④ target cell maximum LDH release group, ⑤ volume correction control group, ⑥ culture medium background group, and ⑦ LDH positive control (optional) group. All the above types were prepared in quadruplicate sets of wells in a round- or V-bottom 96-well tissue culture plate. The same medium and final volume will be used for cytotoxicity assays in 100 μl/well. The cytotoxicity assay plate was incubated for 4 hours in a humidified chamber at 37°C, 5% CO2. Forty-five minutes prior to harvesting supernatants, 10 μl of lysis solution was added for every 100 μl of target cells to the wells containing the target cell maximum LDH release control. After the 4-hour incubation, the plate was centrifuged at 1000 r/min for 4 minutes. Fifty μl aliquots were transfered from all wells using a multichannel pipettor to a fresh 96-well flat-bottom (enzymatic assay) plate. Fifty μl of reconstituted substrate mix was added to each well of the enzymatic assay plate containing samples transferred from the cytotoxicity assay plate. The plate was covered with foil or an opaque box to protect it from light and incubate for 30 minutes at room temperature. Then 50 μl of stop solution was added to each well. The absorbance at 492 nm was recorded within one hour after the addition of stop solution. Statistical analysis Data were expressed as mean±standard deviation (SD). Differences among groups were assessed by general linear models (GLM) and differences between two groups were assessed by q test. P <0.05 was considered statistically significant. RESULTS Expression of HLA-I and HLA-II on peripheral blood lymphocytes The mean fluoresecence intensity of HLA class I on peripheral blood lymphocytes in patients with chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma were 335.80, 309.78, and 114.04 respectively, which had significant difference from normal control (P<0.01). The expressive percentage of HLA class I in patients with chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma were 99.24%, 97.84%, and 96.45% respectively, which had no significant difference from the normal control (P>0.05, Table).Table: Expression of HLA and activity of LAK cell killing HepG2 cells in four groupsThe expressive percentage of HLA class II in patients with chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma were 38.28%, 42.21%, and 52.75% respectively, which were signifcantly different among the groups (P<0.01); but there was no significant difference between the patients with chronic hepatitis B and normal control (P>0.05). The mean fluoresecence intensity of HLA class II on peripheral blood lymphocytes in patients with chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma were 66.0, 77.36, and 88.96 respectively, which were not significantly different from normal control (P>0.05, Table). Killing activity of lymphokine activated killer cell Induced by IL-2 in vitro, the killing activity of peripheral blood lymphocyte was significantly lower in patients with chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma than that in normal control. With the aggravation of disease, the killing activity of peripheral blood lymphocytes had the tendency of progressive decrease in patients with chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma (Table and Fig.).Fig.: Micrographs of lymphocytes killing tumor cells in different groups (HE, original magnification ×400). A: normal control group, LAK cells compress and invade tumor cells; B: chronic hepatitis B group, LAK cells surround tumor cells like satellites, the degree of LAK cells compressing tumor cell is lower than that in normal control; C: hepatic cirrhosis group, the degree of LAK cells aggregating towards tumor cell is lower than that in chronic hepatitis B group. The phenomenon of compression is less than that in B; D: hepatocellular carcinoma group, the phenomenon of aggregation and compression is less than that in hepatic cirrhosis group.DISCUSSION Viruses are cleaned up primarily by cytotoxic activity of CD8+ CTL which effect only by identifying viral antigen presented by HLA-I molecule, so presence of HLA-I molecule is essential condition for killing viruses. Karino et al5 suggested that the expression of HLA class I on hepatocytes had some correlation with the expression of HLA class I on peripheral blood lymphocytes. Le morvan et al6 reported that the expression of HLA on peripheral blood lymphocytes decreased with age. With RT-PCR technology, they also confirmed that the decrease of the expression of HLA class I on peripheral blood lymphocytes would lead to discrepancy in antigen-presenting ability on transcriptional level, which would degrade the reactivity of CD8+ CTL. In this research, we evaluated the expression of HLA class I on peripheral blood lymphocytes to reflect host HLA class I expression all over the body. The mean fluoresecence intensity of HLA class I on peripheral blood lymphocytes were all significantly lower in patients with chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma than that in normal control group, which suggests that density of HLA class I expression on peripheral blood lymphocytes degrades, leading to discrepancy in antigen-presenting ability and the reactivity of CD8+ CTL accordingly. One reason might be that HBV degrades HLA class I expression by releasing inhibiting factor, makes CTL unable to activate and impair the ability of cleaning viruses and finally leads to the infection of HBV persisting and protracting. At the same time, the decrease in HLA class I expression weakens the effect of CTL monitoring tumor cells which might be one factor of hepatocellular carcinoma' liability. The decrease in HLA class I expression on peripheral blood lymphocytes in patients with hepatocellular carcinoma might be one of reasons for tumor's immune escaping. Induced and cultured in vitro, the killing activity of peripheral blood lymphocyte reflected cellular immunity ability of host.7,8 In the study, we detected that with the aggravation of HBV infection, the decrease in killing activity had positive relevance with the decrease in the expression of HLA class I on peripheral blood lymphocytes, most significantly in patients with hepatocellular carcinoma. HBcAg accumulates in cytoplasm of hepatocytes infected by HBV, and HLA class II expression on hepatocytes increases at the same time. When anti-HBc identifies hepatocytes infected by HBV, it will mediated lethal effect by antibody dependent cellular cytotoxicity. Stolarz et al9 discovered significant difference in the expression of HLA-II among patients with chronic hepatitis B, hepatic cirrhosis, hepatocellular carcinoma and normal control. Moreover, HLA-II intensity would increase with aggravation of inflammation activity. Our findings display that the expressive percentage of HLA class II on peripheral blood lymphocytes were significantly higher in patients with hepatic cirrhosis and hepatocellular carcinoma than that in normal control group, but there was no significant difference in mean fluoresecence intensity of HLA-II among patients with chronic hepatitis B, hepatic cirrhosis, hepatocellular carcinoma and normal control, which indicates that B or CD4+ Th cells were up-regulated in these patients. The expression of HLA class I on host peripheral blood lymphocytes reflects its immune competence of anti-virus and anti-tumor. The decrease in host HLA-I expression, leading to the unresponsiveness of CTL due to default of antigen presentation may play an important role in chronic persistence of chronic hepatitis B and malignant conversion to hepatocellular carcinoma. Compared with the pathological region, evaluation of host HLA-I expression all over the body is more simple and convenient and may have broad applying perspective in clinical diagnosis, curing monitoring and prognostic judgement of viral infectious diseases and tumor.